Expert Interview
A First look at Regeneron's Libtayo (cemiplimab) and Fianlimab (LAG-3 inhibitor) combo as a novel treatment for melanoma
Ticker(s): REGNInstitution: New York Presbyterian
- experience both in academic and community medicine and also serves as an oncologist in practice for 15 years
- focuses on providing high level cutting edge care to a variety of cancer patients and also holds a keen interest in the development of new businesses and innovative medical care
- in depth experience with latesttechnologies in cancer care including next generation sequencing and liquid biopsies as well as other new developments.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
